TherapeuticsMD (TXMD) Tops Q2 EPS by 1c

TherapeuticsMD (NYSE: TXMD) reported Q2 EPS of ($0.10), $0.01 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.91 million.

At June 30, 2017, cash on hand was approximately $96.5 million, compared with approximately $131.5 million at December 31, 2016.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• Five Point Holdings, LLC (FPH) Reports Q1 EPS of $0.03
• Southern First Bancshares, Inc. (SFST) Misses Q1 EPS by 8c